http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021518393-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39591 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 |
| filingDate | 2019-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2021518393-A |
| titleOfInvention | Treatment and prevention of amyloidosis |
| abstract | Methods for treating AL amyloidosis associated with the deposition of misfolded immunoglobulin light chain proteins and corresponding uses associated with antibodies such as 2A4 antibodies, or pharmaceutical formulations comprising the aforementioned antibodies. The present disclosure relates to the treatment of AL amyloidosis with the deposition of a misfolded immunoglobulin light chain protein having the amino acid sequence GD at positions 81-82 (Kabat numbering). In some aspects of the disclosure, treatment of AL amyloidosis comprises administering to the patient an effective dosage of the antibody. In some aspects of the disclosure, the antibody is a chimeric antibody. In some aspects of the disclosure, the antibody is a humanized antibody. In some aspects of the disclosure, the antibody is an antigen-binding fragment of the antibody, such as a Fab fragment, Fab'fragment, F (ab') 2 fragment, F (ab) c fragment, Dab, Nanobody, or Fv fragment. be. |
| priorityDate | 2018-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 123.